γδ T cells modulate anti-tumor immunity in small cell lung cancer.

High γδ T cell infiltration in small cell lung cancer predicts improved response to anti-PD-L1 immunotherapy.

• Why it matters: Small cell lung cancer's resistance to anti-PD-(L)1 treatments is partly due to epigenetic silencing of MHC-I, highlighting the need for alternative immune recognition mechanisms to improve outcomes.
• What they did: Using single-cell approaches, the study identified γδ T cell infiltration in patient biospecimens and demonstrated their cytotoxic profile and effectiveness in preclinical models, including their role in T cell engager therapy and sensitization with zoledronate.
• The result: Engaged γδ T cells may serve as valuable targets for SCLC therapy, potentially enhancing treatment responses and offering new avenues beyond MHC-I-dependent immune mechanisms.